iCAD (NASDAQ:ICAD) Rating Lowered to Sell at StockNews.com

iCAD (NASDAQ:ICADGet Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

iCAD Trading Down 15.1 %

iCAD stock opened at $3.14 on Friday. The firm has a market capitalization of $83.34 million, a PE ratio of -24.15 and a beta of 1.40. iCAD has a 12-month low of $1.18 and a 12-month high of $3.78. The firm has a 50-day moving average price of $1.96 and a 200-day moving average price of $1.72.

Hedge Funds Weigh In On iCAD

A number of large investors have recently bought and sold shares of the business. waypoint wealth counsel increased its stake in shares of iCAD by 44.0% in the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after acquiring an additional 4,400 shares during the period. Summit Trail Advisors LLC purchased a new position in shares of iCAD during the 4th quarter valued at about $214,000. Finally, Essex LLC acquired a new position in shares of iCAD in the 3rd quarter valued at about $216,000. Hedge funds and other institutional investors own 24.61% of the company’s stock.

About iCAD

(Get Free Report)

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.

Recommended Stories

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.